GL1X · GenesisL1 explorer

MolNFT v1 · #27480 · protein

Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5- methyl-1,3,4-oxadiazole,-benzothiazole, and-benzimidazole, inhibitors of muscle glycogen phosphorylase B. evidence for a new binding site.

1XL0 · Glycogen phosphorylase, muscle form: “Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5- methyl-1,3,4-oxadiazole,-benzothiazole…”. X-ray diffraction, 2 ligands (OX2, PLP), 12 pockets (best druggability 0.85).…

PDB
1XL0
Type
protein
Length
810 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Glycogen phosphorylase, muscle form
EC
2.4.1.1
UniProt
P00489
Ligands
OX2, PLP
Pockets
12 · best druggability 0.85

Structure

x-ray diffraction · 1 distinct chain · 53% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AGlycogen phosphorylase, muscle form (EC 2.4.1.1)protein81053% helix, 15% strandP00489

Ligands and binding sites

  • OX2 · (1R)-1,5-anhydro-1-(5-methyl-1,3,4-oxadiazol-2-yl)-D-glucitol · ligand · chains A
  • PLP · Pyridoxal-5'-phosphate · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

12 pockets found on a 1 Å grid, 6 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12800.850.9650OX2, PLP
2800.720.9628empty
32560.680.8435empty
4970.510.8320empty
52190.510.7620empty

Modifications

Observed in the structure: 1 cofactor (pyridoxal phosphate Schiff base).

Compared structures

  • 1XL0 · Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazol… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.